Establishing biomarkers for COVID-19 that indicate which patients are likely to develop severe disease could help clinicians to categorize patients earlier, improve prognosis and prioritize treatment.
Click here to find out more about Abcam’s SimpleStep ELISA® for blood biomarkers.